Navigation Links
Pharsight Expands Global Consulting Services Teams
Date:10/15/2007

New Hires and Expanded Internship Program Strengthen Strategic Consulting

Services, Reporting and Analysis Staff in Europe and Canada

MOUNTAIN VIEW, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced the expansion of its scientific consulting services practices with three new hires. Pharsight has also expanded its internship program, which is designed to foster knowledge of modeling and simulation amongst graduate students in a variety of scientific disciplines.

Pharsight has hired Lars Lindbom, Ph.D., as a senior associate scientist in its Strategic Consulting Services (SCS) group, based in Europe. Dr. Lindbom joins Pharsight from Uppsala University's department of Pharmaceutical Biosciences in Sweden, where he held a postdoctoral research fellowship sponsored by Pfizer. He also served as a bioinformatics software systems developer within the discovery research organization at AstraZeneca. Dr. Lindbom has broad experience with population pharmacokinetic and pharmacodynamic (PK/PD) modeling and pharmacometric method development, with an emphasis in computer-intensive statistical methods.

Dr. Lindbom holds a Ph.D. from Uppsala University's department of Pharmaceutical Biosciences, within the National Network in Drug Development, Swedish Foundation for Strategic Research. Dr. Lindbom has authored or co- authored several original research articles in the field of pharmacostatistical modeling and has given invited presentations on Perl- speaks-NONMEM (PsN), a collection of computer programs aiding in the development of non-linear mixed effects models using NONMEM, to which he was a developer and remains an active contributor.

Pharsight's recently launched Reporting and Analysis Services (RAS) business unit has added a PK scientist in response to increased global demand for the group's PK/PD analysis and reporting services. The RAS team has also added a Quality Assurance Inspector to support delivery of high quality, regulatory-compliant clinical study analyses and reports for new drug approval. Since its launch in May 2007, the RAS unit has more than tripled its staff and has plans to expand its facilities in Montreal, Canada. In addition, the RAS unit has accepted into its internship program a student working towards a Ph.D. in Pharmaceutical Sciences at the University of Montreal.

"The addition of new expert staff in both the SCS and RAS business units will further enhance our ability to address the full spectrum of client needs in modeling and simulation," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "Lars brings to SCS a wealth of expertise in the area of PK/PD modeling and advanced statistical methods. The addition of yet another talented, highly experienced scientist in the SCS group will help us meet the growing demand for applying model-based drug development approaches to support our client's decision-making processes."

"In addition to the expansion of the SCS team, we have continued to grow our RAS group's capabilities by bringing on new talent," continued Mr. O'Connor. "Requirements for regulatory-compliant analysis and reporting of PK/PD data to support new drug submissions has driven new customer demand for our RAS offering. We are pleased to extend Pharsight's internship program to cover our entire consulting services practice, which provides talented Ph.D. students with opportunities to work on projects and gain in-depth modeling and simulation expertise. We look forward to contributions from our newest colleagues that will further enhance the services that we provide to our clients."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. The Cleveland Clinic Expands Its Services across the World via the Net
2. Ranbaxy Expands By Acquiring A Generic Company In Belgium
3. Insulin and Growth Hormone, Expands Life Span?
4. Health Insurance Company Expands Product Range
5. Bird Flu Outbreak Expands in Vietnam
6. Skin Cancer Research To Go Global
7. Dementia - a global problem
8. Obesity a global problem
9. Suggestions to reduce global heart disease burden
10. Drop in global deaths from measles
11. First global SARS meet opens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 2016 , ... An April Gallup survey found rising health care costs to ... Sun Health Senior Living (SHSL) may not share those same worries thanks to ... for the year, while holding the line on increasing their contributions, including premiums, deductibles ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life Science ... the organization has earned its ISO 13485 certification, indicating the company’s quality control ... rules and policies associated with ISO quality standard 13485. , BSI Group ...
(Date:5/26/2016)... Texas (PRWEB) , ... May 26, 2016 , ... ... Friday, May 13 at Blackhorse Golf Club in Cypress. With the help of community ... non-profit that restores, empowers, and renews hope for wounded service members and their families ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management and ... Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI Institute ... of the Institute for Functional Medicine. , He also heads up FITTLab, the comprehensive ...
(Date:5/26/2016)... ... ... Bunion Bootie , the manufacturer of the newest and best in ... customer demand over the Mother’s Day Weekend promotion. So much so, that they completely ... completely replenished its inventory levels, it hopes to continue its current sales pace, and ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
(Date:5/24/2016)... 2016  Diana Russell suffers from a form of ... inside out.  This disease has put her in a ... and grandchildren to leave her home.  Because of the ... haul the wheelchair.  So if there is a family ... is left to wait for the bus. ...
(Date:5/24/2016)... May 24, 2016 The ... world , s first dual therapy stent, ...   OrbusNeich, a global company specializing in ... portfolio to include products to treat peripheral artery disease. ... first entry devices for lower limb and arteriovenous (AV) ...
Breaking Medicine Technology: